PCV/mycoplasma hyopneumoniae/PRRS combination vaccine

1. A trivalent immunogenic composition comprising a soluble portion of a Mycoplasma hyopneumoniae ( M.hyo ) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a porcine reproductive and respiratory syndrome (PRRS) virus antigen, wherein the soluble portion of the M.hyo preparation comprises M.hyo -specific soluble protein antigens and is substantially free of insoluble material and both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

2. The composition of claim 1 , wherein the soluble portion of the M.hyo preparation has been treated with protein-A or protein-G prior to being added to the immunogenic composition.

3. The composition of claim 1 , wherein the soluble portion of the M.hyo preparation and the PCV2 antigen are in the form of a ready-to-use liquid composition.

4. The composition of claim 1 , wherein the PRRS virus antigen is a genetically modified live virus.

5. The composition of claim 4 , wherein the genetically modified live PRRS virus is in the form of a lyophilized composition.

6. The composition of claim 1 , wherein the composition elicits a protective immune response in a pig against M.hyo , PCV2 and PRRS virus.

7. The composition of claim 1 , wherein the PCV2 antigen is in the form of a chimeric type-1-type 2 circovirus, said chimeric virus comprising an inactivated recombinant porcine circovirus type 1 expressing the porcine circovirus type 2 ORF2 protein.

8. The composition of claim 1 , wherein the PCV2 antigen is in the form of a recombinant ORF2 protein.

9. The composition of claim 8 , wherein the recombinant ORF2 protein is expressed from a baculovirus vector.

10. The composition of claim 1 , wherein the composition further comprises an adjuvant.

11. The composition of claim 10 , wherein the adjuvant is selected from the group consisting of an oil-in-water adjuvant, a polymer and water adjuvant, a water-in-oil adjuvant, an aluminum hydroxide adjuvant, a vitamin E adjuvant and combinations thereof.

12. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

13. The composition of claim 1 , wherein the composition elicits a protective immune response against M.hyo, PCV2 and PRRS virus when administered as a single dose administration.

14. A method of immunizing a pig against M.hyo , PCV2, and PRRS virus, which comprises administering to the pig the composition of claim 1 .

15. The method of claim 14 , wherein the composition is administered intramuscularly, intradermally, transdermally, or subcutaneously.

16. The method of claim 14 , wherein the composition is administered in a single dose.

17. The method of claim 14 , wherein the composition is administered to pigs having maternally derived antibodies against at least one of M.hyo , PCV2, and PRRS virus.

18. The method of claim 14 , wherein the composition is administered to pigs at 3 weeks of age or older.

19. A kit comprising: a first bottle comprising a composition including both a PCV2 antigen and the soluble portion of a Mycoplasma hyopneumoniae ( M.hyo ) whole cell preparation, wherein the soluble portion of the M.hyo preparation comprises M.hyo -specific soluble protein antigens and is substantially free of insoluble material and both (i) IgG and (ii) antigen/immunoglobulin immunocomplexes; and a second bottle comprising PRRS virus antigen.

20. The kit of claim 19 , wherein the composition in the first bottle of the kit is provided as a ready-to-use liquid composition.

21. The kit of claim 19 , wherein the PRRS virus antigen in the second bottle is in the form of a lyophilized composition.